Apixaban or Vitamin K Antagonists for Stroke Prevention in Patients With Atrial Fibrillation on Hemodialysis: Results of the Randomized Axadia-AFNET 8 Trial

被引：0
|
作者：
Reinecke, Holger [1 ]
Bauersachs, Rupert [2 ]
Breithardt, Gunter [3 ]
Engelbertz, Christiane [3 ]
Gerss, Joachim [4 ]
Gaerlich, Dennis [4 ]
Juergensmeyer, Sabine [5 ]
Wanner, Christoph [6 ]
Kirchhof, Paulus [7 ]
机构：
[1] Univ Hosp Muenster, Dept Cardiol, Munster, Germany
[2] Agaples Bethanien Hosp, Med Care Cntr, Frankfurt, Germany
[3] Univ Hosp Muenster, Dept Cardiol, Munster, Germany
[4] Univ Munster, Inst Biostat & Clin Rsch, Munster, Germany
[5] Atrial Fibrillat Network, Munster, Germany
[6] Univ Hosp, Div Nephrol, Dept Med, Wurzburg, Germany
[7] Univ Hosp Hamburg Eppendorf, Dept Cardiol, Hamburg, Germany
来源：
CIRCULATION | 2022年 / 146卷 / 25期
关键词：
atrialfibrillation; apixaban; vitamin K antagonist; hemodialysis; randomized; controlled trial; stroke prevention;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
18519
引用
收藏
页码：E589 / E590
页数：2
相关论文
共 50 条
  • [21] Safety and Effectiveness Outcomes between Apixaban Versus Vitamin K Antagonists in Atrial Fibrillation Patients on Dialysis
    Guo, Zongwen
    Wang, Yufan
    Ding, Xiaoli
    Lai, Jiying
    Chen, Yijian
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2024, 25 (09)
  • [22] Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design
    Jain, Sneha S.
    Mahaffey, Kenneth W.
    Pieper, Karen S.
    Shimizu, Wataru
    Potpara, Tatjana
    Ruff, Christian T.
    Kamel, Hooman
    Lewis, Basil S.
    Cornel, Jan H.
    Kowey, Peter R.
    Horrow, Jay
    Strony, John
    Plotnikov, Alexei N.
    Li, Danshi
    Weng, Stephen
    Donahue, Julia
    Gibson, C. Michael
    Steg, P. Gabriel
    Mehran, Roxana
    Weitz, Jeffrey I.
    Johnston, S. Claiborne
    Hankey, Graeme J.
    Harrington, Robert A.
    Lam, Carolyn S. P.
    AMERICAN HEART JOURNAL, 2024, 277 : 145 - 158
  • [23] Atrial fibrillation therapy and stroke prevention in hemodialysis patients
    Osmancik, Pavel
    Melenovsky, Vaclav
    KARDIOLOGIA POLSKA, 2023, 81 (12) : 1193 - 1204
  • [24] DUAL ANTIPLATELET THERAPY OR APIXABAN IN PATIENTS INELIGIBLE FOR VITAMIN-K ANTAGONISTS FOR STROKE PREVENTION IN ATRIAL FIBRILLATION: LESSONS FROM THE RECENT ASPIRIN-CONTROLLED TRIALS
    Focks, Jeroen Jaspers
    Brouwer, Marc A.
    Verheugt, Freek W. A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E61 - E61
  • [25] Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation
    Hanna, Michael S.
    Mohan, Puneet
    Knabb, Robert
    Gupta, Elora
    Frost, Charles
    Lawrence, John H.
    PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: WINNERS AND FINALISTS FOR THE PRIX GALIEN USA AWARDS 2013, 2014, 1329 : 93 - 106
  • [26] Apixaban triumphs over aspirin for stroke prevention in patients with atrial fibrillation
    Alexandra King
    Nature Reviews Cardiology, 2011, 8 (4) : 181 - 181
  • [27] Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomized, open-label, non-inferiority trial
    Estes, N. A. Mark, III
    HEART RHYTHM, 2008, 5 (06) : 906 - 906
  • [28] Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study
    Buller, H. R.
    Halperin, J.
    Hankey, G. J.
    Pillion, G.
    Prins, M. H.
    Raskob, G. E.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (06) : 824 - 830
  • [29] Dabigatran, rivaroxaban, and apixaban versus vitamin K antagonists for atrial fibrillation patients at low to intermediate stroke risk: a Danish nationwide cohort study
    Dukanovic, A.
    Staerk, L.
    Fosbol, E. L.
    Sindet-Pedersen, C.
    Bonde, A. N.
    Lorentzen, A. G.
    Gislason, G. H.
    Torp-Pedersen, C.
    Olesen, J. B.
    EUROPEAN HEART JOURNAL, 2017, 38 : 770 - 770
  • [30] Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial
    Ezekowitz, Michael D.
    Pollack, Charles V., Jr.
    Halperin, Jonathan L.
    England, Richard D.
    Nguyen, Sandra VanPelt
    Spahr, Judith
    Sudworth, Maria
    Cater, Nilo B.
    Breazna, Andrei
    Oldgren, Jonas
    Kirchhof, Paulus
    EUROPEAN HEART JOURNAL, 2018, 39 (32) : 2959 - 2971
12345